NCT06793709 is a clinical trial of No Intervention in Biliary Tract Cancer, sponsored by Eisai Co., Ltd..

Who is sponsoring NCT06793709?

NCT06793709 is sponsored by Eisai Co., Ltd..

What drugs are being tested in NCT06793709?

Interventions in NCT06793709: No Intervention.

What condition does NCT06793709 study?

NCT06793709 studies Biliary Tract Cancer.

Is NCT06793709 still recruiting?

NCT06793709 is currently recruiting now. Last updated 27 February 2026.

Last reviewed 2026-02-27 · How we verify

NCT06793709

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy

Recruiting now Last updated 27 February 2026

What this trial tests

trial testing No Intervention in Biliary Tract Cancer in 60 participants. Currently enrolling.

Timeline

10 July 2025

Primary endpoint
20 November 2032

20 November 2032

Quick facts

Lead sponsor	Eisai Co., Ltd.
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	60
Start date	10 July 2025
Primary completion	20 November 2032
Estimated completion	20 November 2032
Sites	1 location across Japan

Drugs / interventions tested

No Intervention

Conditions studied

Biliary Tract Cancer — all drugs for Biliary Tract Cancer →

Sponsor

Eisai Co., Ltd. — full company profile →

Who can join

Eligibility, any sex, with Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to investigate the safety of Tasfygo.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting

Other recruiting trials for Biliary Tract Cancer

Currently open trials in the same condition.

NCT07221253 — A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Bili · Phase 3 · recruiting
NCT06529718 — Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients · Phase 2 · recruiting
NCT07151118 — ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer · recruiting
NCT07142226 — Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC · recruiting
NCT07135544 — A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initial · Phase 2 · recruiting

Other Eisai Co., Ltd. trials

Trials by the same sponsor.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed
NCT05594589 — A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06793709 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 27 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06793709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing